APHIS Seeks Extension and Revision for Veterinary Biologics Oversight Under Virus-Serum-Toxin Act
The United States Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) recently signaled its intention to pursue a revision to and extension of approval for a crucial information collection. This move, announced in the Federal Register, pertains to APHIS's regulatory duties under the long-standing Virus-Serum-Toxin Act and its implementing regulations.
Foundations of Animal Health Protection
Enacted to safeguard the nation's animal population, the Virus-Serum-Toxin Act (21 U.S.C. 151-159) empowers APHIS to establish and enforce regulations preventing the importation, preparation, sale, or shipment of harmful veterinary biological products. These products encompass a wide array of substances, including viruses, serums, toxins, vaccines, and antitoxins, all designed for the diagnosis, treatment, or prevention of diseases in domestic animals. The regulatory framework, detailed in 9 CFR parts 102 through 124, is designed to ensure that all such products used within the country are not only pure and safe but also potent and effective. This robust oversight protects both animal welfare and agricultural economic interests by mitigating disease spread and ensuring reliable animal health interventions.
The Mandate for Information Collection
To effectively carry out its protective mission, APHIS requires a comprehensive array of information from entities involved in the veterinary biological products industry. This information collection is vital for several key regulatory functions. These include the issuance of licenses to qualified establishments that produce these products and permits to importers. APHIS also meticulously tracks personnel qualifications, reviews packaging and labeling, authorizes shipments, and mandates product and test reports. Other crucial data points collected include requests for materials, preparation and usage requests, development and field study summaries, and notifications regarding stop distribution and sale actions, along with associated inventories and due diligence petitions. Additionally, robust recordkeeping is a fundamental requirement.
The collection of this data allows APHIS to maintain a stringent watch over the entire lifecycle of veterinary biological products, from development and manufacturing to distribution and use. Without this detailed information, the agency's ability to verify product quality and compliance would be severely hampered, potentially exposing domestic animals to ineffective or harmful substances.
Proposed Adjustments to Administrative Burden
APHIS is now seeking approval from the Office of Management and Budget (OMB) for an additional three years of this information collection. Notably, the agency has amended the collection's estimates. While the estimated annual number of responses per respondent and the individual burden per response are projected to decrease, APHIS anticipates an increase in the estimated annual number of respondents and the overall annual number of responses. This results in an increased estimated total annual burden on respondents, now estimated at 53,859 hours. The individual average burden per response is calculated at a minuscule 0.001 hours, suggesting that while the total volume of interactions is rising, the specific effort for each interaction is minimal.
This shift in estimates suggests that APHIS may be expanding its regulatory reach to a greater number of entities, or that the industry itself is growing, requiring more interactions despite streamlined processes for individual submissions. The changes reflect an adaptive approach to regulatory oversight in a dynamic industry.
Opportunity for Public Participation
In line with the Paperwork Reduction Act of 1995, APHIS has opened a public comment period, inviting input from interested parties. This period concludes on August 31, 2026. Comments will aid APHIS in evaluating the necessity and utility of the information, assessing the accuracy of burden estimates, enhancing data quality, and exploring ways to minimize the burden on respondents through automation and other technologies.
Stakeholders, including veterinary biological product developers and producers, as well as foreign and state government officials, and private individuals, are encouraged to submit their feedback. All comments received will be summarized and included in APHIS's request for OMB approval and will become part of the public record.
Implications for Industry and Animal Health
The ongoing commitment by APHIS to review and renew its information collection practices under the Virus-Serum-Toxin Act underscores the critical importance of federal oversight in veterinary biologics. For manufacturers and importers, it means continued engagement with detailed reporting requirements, albeit potentially with a more distributed workload. For animal owners and the agricultural sector, it offers assurance that the products used to protect and treat livestock and pets are subject to rigorous federal standards. This regulatory continuity is essential for maintaining confidence in the safety and efficacy of animal health interventions and for protecting the broader agricultural economy from disease outbreaks. The upcoming comment period provides a vital opportunity for stakeholders to help shape the future of this essential regulatory framework.
